Solid Biosciences LLC (SLDB)

Solid Biosciences Inc. is a biotechnology company focused on developing therapies for neuromuscular and cardiac diseases in the United States. Its lead program, SGT-003, is in phase 1/2 development for Duchenne muscular dystrophy. The pipeline also includes SGT-212 for Friedreich's ataxia in phase 1b, along with several earlier-stage candidates: SGT-501 for catecholaminergic polymorphic ventricular tachycardia, SGT-601 for TNNT2-mediated dilated cardiomyopathy, SGT-401 for BAG3-mediated dilated cardiomyopathy, and SGT-701 for a rare inherited disorder linked to RBM20 mutations. The company is also developing platform technologies that include capsid libraries, genetic regulators, immunomodulation approaches, manufacturing purity methods, and dual gene expression systems. Solid Biosciences has collaboration and license agreements with Ultragenyx Pharmaceutical Inc., the University of Washington, the University of Missouri, the University of Florida, and ICS Maugeri S.p.A. Incorporated in 2013, the company is headquartered in Charlestown, Massachusetts.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.